Find your next paid study

J-Pharma Co., Ltd.NCT07265674

Gastric or Gastroesophageal Junction AdenocarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)+1 more

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharma…

Phanes TherapeuticsNCT05482893

Selected Advanced Solid TumorsColorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+4 more

A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors

This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors. SKL35502 is …

SK Life Science, Inc.NCT07812805

Solid Tumor CancerLocally AdvancedMetastatic Solid Tumors+5 more

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and …

Avenzo Therapeutics, Inc.NCT07038343

Colorectal CancerGastro Esophageal Junctional CancerGastric Cancer (GC)+5 more

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of the IKS04 Regimen Targeting CA242

This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify…

Iksuda Therapeutics Ltd.NCT07738939

Phase 3

Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). …

Biliary Tract Cancer (BTC)

InnoPharmax Inc.NCT06622057

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

SEED Therapeutics, Inc.NCT07197554

Solid TumorAdvanced CancerMetastatic Cancer+5 more

A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with…